

The Australian Imaging, Biomarkers and Lifestyle (AIBL)  
baseline characteristics of 1112 individuals recruited for  
Alzheimer's disease

International Psychogeriatrics

21, 672-687

DOI: [10.1017/s1041610209009405](https://doi.org/10.1017/s1041610209009405)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Relationship between atrophy and $\beta$ -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	5.3	322
4	Plasma Amyloid- $\beta$ as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	2.6	122
5	Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 399-404.	6.4	2
6	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. <i>Acta Neuropathologica</i> , 2010, 120, 385-399.	7.7	79
8	$\beta$ -Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. <i>Neurology</i> , 2010, 74, 121-127.	1.1	209
9	The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. <i>International Psychogeriatrics</i> , 2010, 22, 1248-1264.	1.0	286
10	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	7.6	130
11	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010, 5, 33-53.	3.0	23
12	Integrating ADNI results into Alzheimer's disease drug development programs. <i>Neurobiology of Aging</i> , 2010, 31, 1481-1492.	3.1	51
13	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	3.1	885
14	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 202.	0.8	443
15	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 291-296.	0.8	53
16	Alzheimer's Disease Neuroimaging Initiative special issue. <i>Neurobiology of Aging</i> , 2010, 31, 1259-1262.	3.1	17
17	Neuroimaging to assess safety and efficacy of AD therapies. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 23-26.	4.1	25
18	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	2.6	83
19	Independent contribution of temporal $\beta$ -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	7.6	132
20	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.	5.7	119
21	Commentary on "Biomarkers in Alzheimer's disease drug development." The view from Alzheimer's Disease Neuroimaging Initiative. , 2011, 7, e45-e47.		0

#	ARTICLE	IF	CITATIONS
22	Assessment of cognition in mild cognitive impairment: A comparative study. <i>Alzheimer's and Dementia</i> , 2011, 7, 338-355.	0.8	85
24	Advances in structural and molecular neuroimaging in Alzheimer's disease. <i>Medical Journal of Australia</i> , 2011, 194, S20-3.	1.7	5
25	A web-based normative data tool for assessing cognitive performance in healthy older Australians. <i>Medical Journal of Australia</i> , 2011, 194, S12-4.	1.7	3
26	Criterion and Construct Validity of the CogState Schizophrenia Battery in Japanese Patients with Schizophrenia. <i>PLoS ONE</i> , 2011, 6, e20469.	2.5	34
27	An international perspective on advanced neuroimaging: cometh the hour or ivory tower?. <i>International Psychogeriatrics</i> , 2011, 23, S58-S64.	1.0	3
28	Examining the nature of impairment in visual paired associate learning in amnesic mild cognitive impairment.. <i>Neuropsychology</i> , 2011, 25, 752-762.	1.3	25
29	Episodic Memory Decline Predicts Cortical Amyloid Status in Community-Dwelling Older Adults. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 627-637.	2.6	34
30	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. <i>Pathology</i> , 2011, 43, 93-102.	0.6	7
31	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	1.6	139
32	Negative argument for debate with V. O. Emery for J Neural Transmission. <i>Journal of Neural Transmission</i> , 2011, 118, 1379-1381.	2.8	3
33	Longitudinal assessment of A $\beta$ and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	5.3	730
34	Contrasting perceptions of health professionals and older people in Australia: what constitutes elder abuse?. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 466-472.	2.7	17
35	Plasma apolipoprotein E and Alzheimer disease risk. <i>Neurology</i> , 2011, 76, 1091-1098.	1.1	142
36	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation. , 2011, , .		5
37	Reliability of Repeated Cognitive Assessment of Dementia Using a Brief Computerized Battery. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011, 26, 326-333.	1.9	61
38	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 173-178.	1.5	115
39	Amyloid imaging. <i>International Psychogeriatrics</i> , 2011, 23, S41-S49.	1.0	29
40	Understanding failure of visual paired associate learning in amnesic mild cognitive impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 1069-1078.	1.3	13

#	ARTICLE	IF	CITATIONS
41	Unrecognised ringside concussive injury in amateur boxers. <i>British Journal of Sports Medicine</i> , 2012, 46, 1011-1015.	6.7	18
42	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 853-863.	1.3	13
43	Validity of a Brief Computerized Cognitive Screening Test in Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2012, 25, 89-99.	2.3	74
44	Prediction of Amyloid- $\beta^2$ Pathology in Amnesic Mild Cognitive Impairment with Neuropsychological Tests. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 451-462.	2.6	31
45	Intense physical activity is associated with cognitive performance in the elderly. <i>Translational Psychiatry</i> , 2012, 2, e191-e191.	4.8	93
46	Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population. <i>Translational Psychiatry</i> , 2012, 2, e164-e164.	4.8	149
47	Neuropsychological Performance and Conversion to Alzheimer's Disease in Early- Compared to Late-Onset Amnesic Mild Cognitive Impairment: CREDOS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 156-166.	1.5	25
48	Prevalence of Apolipoprotein E4 Genotype and Homozygotes (APOE e4/4) among Patients Diagnosed with Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2012, 38, 1-17.	2.3	261
49	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012, 24, 197-204.	1.0	39
50	Could cholinesterase inhibitors be harmful over the long term?. <i>International Psychogeriatrics</i> , 2012, 24, 171-174.	1.0	21
51	Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.1	96
52	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <i>Neurology</i> , 2012, 79, 897-905.	1.1	208
53	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.5	348
54	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012, 8, S1-68.	0.8	432
55	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	1.3	111
56	Accelerated cortical atrophy in cognitively normal elderly with high $\beta^2$ -amyloid deposition. <i>Neurology</i> , 2012, 78, 477-484.	1.1	151
57	Markov random field and Gaussian mixture for segmented MRI-based partial volume correction in PET. <i>Physics in Medicine and Biology</i> , 2012, 57, 6681-6705.	3.0	32
58	Intraindividual cognitive decline using a brief computerized cognitive screening test. <i>Alzheimer's and Dementia</i> , 2012, 8, 95-104.	0.8	66

#	ARTICLE	IF	CITATIONS
59	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	2.6	40
60	Visual Systems for Interactive Exploration and Mining of Large-Scale Neuroimaging Data Archives. <i>Frontiers in Neuroinformatics</i> , 2012, 6, 11.	2.5	22
61	Do brain image databanks support understanding of normal ageing brain structure? A systematic review. <i>European Radiology</i> , 2012, 22, 1385-1394.	4.5	11
62	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012, 205, 96-109.	2.5	17
63	<sup>18</sup> F-florbetaben A $\beta$ imaging in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 4.	6.2	49
64	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. <i>BMC Psychology</i> , 2013, 1, 30.	2.1	153
65	Blood-Based Biomarkers in Alzheimer Disease: Where Are We Now and Where Have We to Go? Reply. <i>JAMA Neurology</i> , 2013, 70, 133.	9.0	2
66	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. <i>Diabetes Care</i> , 2013, 36, 2981-2987.	8.6	308
67	Predicting Alzheimer disease with <sup>18</sup> F-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. <i>Annals of Neurology</i> , 2013, 74, 905-913.	5.3	194
68	Efficient brain lesion segmentation using multi-modality tissue-based feature selection and support vector machines. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2013, 29, 905-915.	2.1	11
69	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 171-182.	2.6	46
70	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013, 9, e111-94.	0.8	535
71	A $\beta$ amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013, 9, 538-545.	0.8	51
72	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 515-531.	2.6	160
73	Amyloid $\beta$ deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	10.2	1,738
74	Positron Emission Tomography in Alzheimer Disease. , 2013, , 131-174.		3
75	Physical activity and amyloid- $\beta$ plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. <i>Molecular Psychiatry</i> , 2013, 18, 875-881.	7.9	185
76	BDNF Val66Met, A $\beta$ amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	3.1	109

#	ARTICLE	IF	CITATIONS
77	Cross-sectional and Longitudinal Analysis of the Relationship Between A $\beta$ Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 903.	9.0	170
78	Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. <i>NeuroImage</i> , 2013, 65, 511-521.	4.2	224
79	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	2.6	42
80	Lack of reliable evidence for a distinctive $\beta$ -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013, 136, 2201-2216.	7.6	28
81	Unusual Clinical and Molecular-Pathological Profile of Gerstmann-StrÅussler-Scheinker Disease Associated With a Novel <i>PRNP</i> Mutation (V176G). <i>JAMA Neurology</i> , 2013, 70, 1180.	9.0	19
82	MilXplore: a web-based system to explore large imaging datasets. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, 1046-1052.	4.4	8
83	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.5	90
84	The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants "at risk" for dementia. <i>International Review of Psychiatry</i> , 2013, 25, 726-737.	2.8	18
85	Clinical Utility of Auditory Memory Testing in a Heart Failure Population. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 444-452.	1.1	4
86	Blood-Based Biomarkers in Alzheimer Disease: Where Are We Now and Where Have We to Go?. <i>JAMA Neurology</i> , 2013, 70, 133.	9.0	6
87	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. <i>International Review of Psychiatry</i> , 2013, 25, 699-710.	2.8	15
88	The association of A $\beta$ amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	1.0	24
89	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- $\beta$ : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	2.6	34
90	Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. <i>Translational Psychiatry</i> , 2013, 3, e233-e233.	4.8	230
91	Accurate segmentation of brain images into 34 structures combining a non-stationary adaptive statistical atlas and a multi-atlas with applications to Alzheimer'S disease. , 2013, 2013, 1202-1205.		9
92	Cognitive consequences of high A $\beta$ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.3	33
93	Effects of education on the progression of early- versus late-stage mild cognitive impairment. <i>International Psychogeriatrics</i> , 2013, 25, 597-606.	1.0	46
94	Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. <i>International Psychogeriatrics</i> , 2013, 25, 1307-1315.	1.0	142

#	ARTICLE	IF	CITATIONS
95	The Anesthesiology, Surgery and Cognition Professional Interest Area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment's Inaugural Satellite Symposium and Featured Research Session Report. <i>Anesthesia and Analgesia</i> , 2013, 116, 953-954.	2.2	0
96	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid- $\beta^2$ . <i>Journal of Alzheimer's Disease</i> , 2013, 33, 675-679.	2.6	62
97	Decreased Copper in Alzheimer's Disease Brain Is Predominantly in the Soluble Extractable Fraction. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-7.	2.0	36
98	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. <i>PLoS ONE</i> , 2014, 9, e84777.	2.5	43
99	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	2.5	75
100	TheHiveDB image data management and analysis framework. <i>Frontiers in Neuroinformatics</i> , 2014, 7, 49.	2.5	82
101	A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H <sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 47-58.	1.4	95
102	Amyloid and <i>APOE</i> $\epsilon^4$ interact to influence short-term decline in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1760-1767.	1.1	246
103	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	1.0	37
104	The importance of longitudinal cohort studies in understanding risk and protective factors for dementia. <i>International Psychogeriatrics</i> , 2014, 26, 541-542.	1.0	2
105	The Preclinical Alzheimer Cognitive Composite. <i>JAMA Neurology</i> , 2014, 71, 961.	9.0	548
106	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.1	125
107	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	1.0	9
108	Preventing cognitive decline in preclinical Alzheimer's disease. <i>Current Opinion in Pharmacology</i> , 2014, 14, 18-22.	3.5	21
109	Physical activity program preferences and perspectives of older adults with and without cognitive impairment. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 179-190.	2.2	44
110	Associations between gonadotropins, testosterone and $\beta^2$ amyloid in men at risk of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2014, 19, 69-75.	7.9	98
111	Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. <i>Computers in Human Behavior</i> , 2014, 30, 199-205.	8.5	35
112	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	7.6	182

#	ARTICLE	IF	CITATIONS
113	A Focus on Structural Brain Imaging in the Alzheimer's Disease Neuroimaging Initiative. <i>Biological Psychiatry</i> , 2014, 75, 527-533.	1.3	35
114	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform. , 2014, , .		21
115	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. <i>Metallomics</i> , 2014, 6, 1216-1219.	2.4	34
116	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. <i>Neurology</i> , 2014, 83, 1345-1352.	1.1	58
117	Statistical normalization techniques for magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2014, 6, 9-19.	2.7	300
118	A systematic review of the evidence that brain structure is related to muscle structure and their relationship to brain and muscle function in humans over the lifecourse. <i>BMC Geriatrics</i> , 2014, 14, 85.	2.7	78
119	Imago Mundi, Imago AD, Imago ADNI. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 62.	6.2	5
120	Do current therapeutic anti- $A\beta$ antibodies for Alzheimer's disease engage the target?. <i>Acta Neuropathologica</i> , 2014, 127, 803-810.	7.7	52
121	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. <i>Translational Neuroscience</i> , 2014, 5, .	1.4	1
122	An anemia of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2014, 19, 1227-1234.	7.9	114
123	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 661-668.	2.6	76
124	$A\beta$ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 743.	0.8	66
125	Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. <i>Annals of Epidemiology</i> , 2014, 24, 63-71.	1.9	61
126	The Italian Alzheimer's Disease Neuroimaging Initiative (I-ADNI): Validation of Structural MR Imaging. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 941-952.	2.6	22
127	Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An $N = 725$ surface-based Alzheimer's disease neuroimaging initiative study. <i>Human Brain Mapping</i> , 2014, 35, 3903-3918.	3.6	62
128	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. <i>Journal of Neuroimmunology</i> , 2014, 273, 65-71.	2.3	87
129	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 53-61.	0.8	114
130	A blood-based predictor for neocortical $A\beta$ burden in Alzheimer's disease: results from the AIBL study. <i>Molecular Psychiatry</i> , 2014, 19, 519-526.	7.9	108



#	ARTICLE	IF	CITATIONS
131	Beyond Statistics: A New Combinatorial Approach to Identifying Biomarker Panels for the Early Detection and Diagnosis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 211-217.	2.6	4
132	Plasma Amyloid- $\beta^2$ Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 95-104.	2.6	41
133	Amyloid- $\beta^2$ Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 677-686.	2.6	63
134	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. <i>BMC Bioinformatics</i> , 2014, 15, S11.	2.6	67
135	O3-06-05: LONGITUDINAL COGNITIVE DECLINE IN THE AIBL COHORT: THE ROLE OF APOE $\epsilon^4$ STATUS. , 2014, 10, P220-P221.		12
136	Comparing the Performance of the HADS and the GDS-15 in the AIBL Study. <i>International Psychogeriatrics</i> , 2015, 27, 1577-1578.	1.0	3
137	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015, 114, 1683-1693.	2.3	5
138	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056.	30.5	1,210
139	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.3	43
140	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in $\beta$ PET Amyloid- $\beta^2$ Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	2.6	47
141	Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 443-452.	2.6	7
142	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	2.6	317
143	Peripheral $\beta$ -Defensins 1 and 2 are Elevated in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1131-1143.	2.6	15
144	Design, implementation and operation of a multimodality research imaging informatics repository. <i>Health Information Science and Systems</i> , 2015, 3, S6.	5.2	5
145	Subjective Memory Complaints in APOE $\epsilon^4$ Carriers are Associated with High Amyloid- $\beta^2$ Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	2.6	45
146	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	2.6	28
147	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 71.	6.2	14
148	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1631-1638.	3.4	9

#	ARTICLE	IF	CITATIONS
149	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. <i>Frontiers in Neurology</i> , 2015, 6, 236.	2.4	102
150	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE $\epsilon$ 4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	2.5	22
151	Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 939-954.	2.6	63
152	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.8	205
153	An adaptive genetic algorithm for selection of blood-based biomarkers for prediction of Alzheimer's disease progression. <i>BMC Bioinformatics</i> , 2015, 16, S1.	2.6	25
154	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. <i>Computerized Medical Imaging and Graphics</i> , 2015, 46, 269-276.	5.8	35
155	Amyloid-beta and depression in healthy older adults: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 36-46.	2.3	66
156	The backup is active in Alzheimer's disease: A hypothesis from problem theory. <i>Medical Hypotheses</i> , 2015, 84, 241-248.	1.5	0
157	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. <i>NeuroImage</i> , 2015, 111, 562-579.	4.2	266
158	Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 917-925.	2.6	13
159	Decreased Plasma Iron in Alzheimer's Disease Is Due to Transferrin Desaturation. <i>ACS Chemical Neuroscience</i> , 2015, 6, 398-402.	3.5	75
160	APOE $\epsilon$ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	3.1	75
161	Basal forebrain atrophy correlates with amyloid $\beta$ 2 burden in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2015, 7, 105-113.	2.7	89
162	Comparison of MR-less PiB SLURV quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	3.1	96
163	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A $\beta$ Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.5	40
164	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015, 11, e1-120.	0.8	261
165	The impact of luteinizing hormone and testosterone on beta amyloid (A $\beta$ 2) accumulation: Animal and human clinical studies. <i>Hormones and Behavior</i> , 2015, 76, 81-90.	2.1	25
166	Longitudinal cognitive decline in the AIBL cohort: The role of APOE $\epsilon$ 4 status. <i>Neuropsychologia</i> , 2015, 75, 411-419.	1.6	27

#	ARTICLE	IF	CITATIONS
167	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. <i>Alzheimer's and Dementia</i> , 2015, 11, 850-859.	0.8	43
168	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Neurobiology of Aging</i> , 2015, 36, 1231-1238.	3.1	71
169	Amyloid- $\beta^2$ , Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	11.0	160
170	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 16.	6.2	22
171	Open referral policy within a nurse-led memory clinic: patient demographics, assessment scores, and diagnostic profiles. <i>International Psychogeriatrics</i> , 2015, 27, 967-979.	1.0	9
172	Blood protein predictors of brain amyloid for enrichment in clinical trials?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 48-60.	2.4	50
173	Semantic enrichment of longitudinal clinical study data using the CDISC standards and the semantic statistics vocabularies. <i>Journal of Biomedical Semantics</i> , 2015, 6, 16.	1.6	16
174	Dietary patterns and cognitive decline in an Australian study of ageing. <i>Molecular Psychiatry</i> , 2015, 20, 860-866.	7.9	111
175	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. <i>Age and Ageing</i> , 2015, 44, 1012-1019.	1.6	31
176	APOE and BDNF polymorphisms moderate amyloid $\beta^2$ -related cognitive decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2015, 20, 1322-1328.	7.9	105
177	$\beta^2$ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 431-436.	1.9	78
178	Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. <i>Molecular Psychiatry</i> , 2015, 20, 1188-1196.	7.9	315
179	Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 105.	3.4	13
180	Cohort profile: Women's Healthy Ageing Project (WHAP) - a longitudinal prospective study of Australian women since 1990. <i>Women's Midlife Health</i> , 2016, 2, 5.	1.5	17
181	Global Data Sharing in Alzheimer Disease Research. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 160-168.	1.3	31
182	Prevalence of Dementia 7.5 Years after Coronary Artery Bypass Graft Surgery. <i>Anesthesiology</i> , 2016, 125, 62-71.	2.5	135
183	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 561-572.	2.6	41
184	$\beta^2$ -related memory decline in APOE $\epsilon^4$ noncarriers. <i>Neurology</i> , 2016, 86, 1635-1642.	1.1	37

#	ARTICLE	IF	CITATIONS
185	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	3.1	34
186	Predictive Factors for Verbal Memory Performance Over Decades of Aging: Data from the Women's Healthy Ageing Project. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 857-867.	1.2	14
187	Cognitive variabilityâ€”A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 47-55.	2.4	22
188	Cognitive and functional changes associated with AÎ² pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	3.1	28
189	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 362-370.	2.3	14
190	The Neurobiology and Age-Related Prevalence of the Îµ4 Allele of Apolipoprotein E in Alzheimerâ€™s Disease Cohorts. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 316-324.	2.3	82
191	Measuring fatigue-related impairment in the workplace. <i>Journal of Engineering, Design and Technology</i> , 2016, 14, 507-525.	1.7	9
192	Predicting Alzheimer disease from a blood-based biomarker profile. <i>Neurology</i> , 2016, 87, 1093-1101.	1.1	26
193	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	10.2	175
194	Domain adaptation for Alzheimer's disease diagnostics. <i>NeuroImage</i> , 2016, 139, 470-479.	4.2	83
195	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2016, 132, 377-389.	7.7	40
196	The Relationship between Sleep Quality and Brain Amyloid Burden. <i>Sleep</i> , 2016, 39, 1063-1068.	1.1	123
197	Rubidium and potassium levels are altered in Alzheimerâ€™s disease brain and blood but not in cerebrospinal fluid. <i>Acta Neuropathologica Communications</i> , 2016, 4, 119.	5.2	39
198	Molecular Imaging in Alzheimer Clinical Trials. , 2016, , 523-563.		0
199	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€”scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 19-26.	2.4	72
200	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 18-26.	2.4	30
201	Early detection of Alzheimer's disease using M<sc>RI</sc> hippocampal texture. <i>Human Brain Mapping</i> , 2016, 37, 1148-1161.	3.6	165
202	Embedding a Recovery Orientation into Neuroscience Research: Involving People with a Lived Experience in Research Activity. <i>Psychiatric Quarterly</i> , 2016, 87, 75-88.	2.1	8

#	ARTICLE	IF	CITATIONS
203	The Image and Data Archive at the Laboratory of Neuro Imaging. <i>NeuroImage</i> , 2016, 124, 1080-1083.	4.2	50
204	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.8	135
205	Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. <i>Metallomics</i> , 2016, 8, 628-632.	2.4	30
206	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. <i>Lancet Psychiatry</i> , 2016, 3, 179-186.	7.4	171
207	Amyloid burden and incident depressive symptoms in cognitively normal older adults. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 455-463.	2.7	49
208	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). <i>Journal of Alzheimer's Disease</i> , 2017, 57, 183-193.	2.6	54
209	APOE $\epsilon$ 4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 411-422.	2.6	9
210	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017, 27, 653-667.	1.9	20
211	Plasma Amyloid- $\beta$ 2 Peptides in Type 2 Diabetes: A Matched Case-Control Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1127-1133.	2.6	14
212	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.8	58
213	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 676.	3.3	35
214	Freesurfer cortical normative data for adults using Desikan-Killiany-Tourville and ex vivo protocols. <i>NeuroImage</i> , 2017, 156, 43-64.	4.2	33
215	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 60-72.	2.4	29
216	Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. <i>Statistics in Medicine</i> , 2017, 36, 2720-2734.	1.6	20
217	Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain. <i>NeuroImage</i> , 2017, 156, 315-339.	4.2	64
218	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1293-1302.	2.6	35
219	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 147-155.	2.4	28
220	Biochemically-defined pools of amyloid- $\beta$ 2 in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017, 140, 1486-1498.	7.6	123

#	ARTICLE	IF	CITATIONS
221	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 193-201.	2.6	12
222	A "Disease Severity Index"™ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017, 7, 44368.	3.3	23
223	Cross-validation of optimized composites for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 123-129.	3.7	18
224	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	6.4	44
225	Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 142-154.	0.5	51
226	Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry. <i>NeuroImage: Clinical</i> , 2017, 13, 470-482.	2.7	134
227	Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 453-460.	1.8	6
228	Plasma amyloid $\beta$ 42/40 ratios as biomarkers for amyloid $\beta$ cerebral deposition in cognitively normal individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 179-187.	2.4	129
229	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of $\beta$ -amyloid load in an AD cohort. <i>Scientific Reports</i> , 2017, 7, 14057.	3.3	22
230	A Multi-armed Bandit to Smartly Select a Training Set from Big Medical Data. <i>Lecture Notes in Computer Science</i> , 2017, , 38-45.	1.3	2
231	Consensus Approaches to Identify Incident Dementia in Cohort Studies: Systematic Review and Approach in the Successful Aging after Elective Surgery Study. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1010-1018.e1.	2.5	11
232	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <i>Scientific Reports</i> , 2017, 7, 9766.	3.3	59
233	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. <i>International Psychogeriatrics</i> , 2017, 29, 1825-1834.	1.0	21
234	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's™ Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	2.6	21
235	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
236	PET-only 18F-AV1451 tau quantification. , 2017, , .		1
237	Amyloid $\beta$ "associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 156-164.	2.4	19
238	Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's™ disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 13.	6.2	88

#	ARTICLE	IF	CITATIONS
239	Joint prediction of multiple scores captures better individual traits from brain images. <i>NeuroImage</i> , 2017, 158, 145-154.	4.2	35
240	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017, 13, 388-398.	0.8	23
241	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
242	The Efficacy of Cognitive Intervention in Mild Cognitive Impairment (MCI): a Meta-Analysis of Outcomes on Neuropsychological Measures. <i>Neuropsychology Review</i> , 2017, 27, 440-484.	4.9	175
243	Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 1178.	9.0	454
244	Cerebral quantitative susceptibility mapping predicts amyloid- $\beta^2$ -related cognitive decline. <i>Brain</i> , 2017, 140, 2112-2119.	7.6	213
245	Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 380.	2.0	32
246	Advances in Studying Brain Morphology: The Benefits of Open-Access Data. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 405.	2.0	29
247	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	1.3	29
248	A Multi-Cohort Study of ApoE $\epsilon^4$ and Amyloid- $\beta^2$ Effects on the Hippocampus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1159-1174.	2.6	36
249	Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics. <i>Psychiatry Investigation</i> , 2017, 14, 851.	1.6	75
250	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 757-771.	3.8	31
251	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain $A\beta^2$ -amyloid burden. <i>Translational Psychiatry</i> , 2018, 8, 47.	4.8	92
252	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. <i>Personalized Medicine in Psychiatry</i> , 2018, 7-8, 14-20.	0.1	13
253	Gaussian process uncertainty in age estimation as a measure of brain abnormality. <i>NeuroImage</i> , 2018, 175, 246-258.	4.2	45
254	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- $\beta^2$ Load and Cognitive Performance in Cognitively Normal Elderly Participants. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 479-487.	2.6	50
255	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid- $\beta^2$ . <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1589-1598.	2.6	44
256	High performance plasma amyloid- $\beta^2$ biomarkers for Alzheimer's disease. <i>Nature</i> , 2018, 554, 249-254.	27.8	1,180

#	ARTICLE	IF	CITATIONS
257	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE $\epsilon$ 4-positive cognitively normal adults with high A $\beta$ -amyloid burden. <i>Scientific Reports</i> , 2018, 8, 2034.	3.3	31
258	Association of $\beta$ -Amyloid and Apolipoprotein E $\epsilon$ 4 With Memory Decline in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 488.	9.0	70
259	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	4.1	27
260	The Latent Structure and Test-Retest Stability of Connected Language Measures in the Wisconsin Registry for Alzheimer's Prevention (WRAP). <i>Archives of Clinical Neuropsychology</i> , 2018, 33, 993-1005.	0.5	10
261	Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2018, 141, 888-902.	7.6	226
262	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	2.6	96
263	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	1.3	19
264	Spanish version of the Mattis Dementia Rating Scale-2 for early detection of Alzheimer's disease and mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 832-840.	2.7	1
265	Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease. <i>Pharmacogenomics Journal</i> , 2018, 18, 209-214.	2.0	19
266	Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment. <i>Molecular Psychiatry</i> , 2018, 23, 767-776.	7.9	48
267	Elevated plasma ferritin in elderly individuals with high neocortical amyloid- $\beta$ load. <i>Molecular Psychiatry</i> , 2018, 23, 1807-1812.	7.9	49
268	Collaborative Facilitation in Older Couples: Successful Joint Remembering Across Memory Tasks. <i>Frontiers in Psychology</i> , 2018, 9, 2385.	2.1	15
269	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1193-1211.	2.6	27
270	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 423.	3.4	16
271	Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundaci3 ACE Healthy Brain Initiative (FACEHBI). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 119.	6.2	46
272	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. <i>Lecture Notes in Computer Science</i> , 2018, , 65-72.	1.3	1
273	Machine Learning for Predicting Cognitive Diseases: Methods, Data Sources and Risk Factors. <i>Journal of Medical Systems</i> , 2018, 42, 243.	3.6	40
274	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	6.2	46



#	ARTICLE	IF	CITATIONS
275	Mediterranean diet adherence and rate of cerebral A $\beta$ -amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. <i>Translational Psychiatry</i> , 2018, 8, 238.	4.8	49
276	Application of B $\bar{A}$ zier Curves for Calculating Likelihood Ratios for Plasma Amyloid- $\beta$ Biomarkers for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 276.	3.4	1
277	Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1 $\alpha$ -42 Peptide in the CSF. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 253.	3.4	25
278	Relationship Between Amyloid- $\beta$ Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1313-1325.	2.6	19
279	Sex, amyloid, and APOE $\epsilon$ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.8	169
280	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1299-1305.	2.6	28
281	Broadening the scope of epidemiologic dementia research. <i>European Journal of Epidemiology</i> , 2018, 33, 617-620.	5.7	2
282	A hybrid computational approach for efficient Alzheimer's disease classification based on heterogeneous data. <i>Scientific Reports</i> , 2018, 8, 9774.	3.3	43
283	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	6.2	62
284	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018, 70, 22-29.	3.0	13
285	Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data. <i>NeuroImage</i> , 2018, 183, 504-521.	4.2	132
286	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 977-988.	2.6	15
287	Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid- $\beta$ load: A pilot study. <i>Scientific Reports</i> , 2018, 8, 8008.	3.3	45
288	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 170-179.	3.1	14
289	Features of Successful and Unsuccessful Collaborative Memory Conversations in Long-Married Couples. <i>Topics in Cognitive Science</i> , 2019, 11, 668-686.	1.9	18
290	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid $\beta$ -Associated Cognitive Decline in Older Adults. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 585-598.	0.5	23
291	APOE $\epsilon$ 4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 647-658.	2.6	22
292	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.1	96

#	ARTICLE	IF	CITATIONS
293	Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm. Handbook of Behavioral Neuroscience, 2019, , 239-246.	0.7	0
294	Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis. Frontiers in Neurology, 2019, 10, 976.	2.4	3
295	Cohort Profile: The ASPREE Longitudinal Study of Older Persons (ALSOP). International Journal of Epidemiology, 2019, 48, 1048-1049h.	1.9	36
296	Including ethnic and cultural diversity in dementia research. Medical Journal of Australia, 2019, 211, 345.	1.7	20
297	Practical algorithms for amyloid $\beta$ probability in subjective or mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 710-720.	2.4	8
298	The Impact of Self-Reported Hearing Difficulties on Memory Collaboration in Older Adults. Frontiers in Neuroscience, 2019, 13, 870.	2.8	5
299	APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER'S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-8.	2.7	20
300	Generative Aging Of Brain MRI For Early Prediction Of MCI-AD Conversion. , 2019, , .		13
301	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.8	7
302	Using path signatures to predict a diagnosis of Alzheimer's disease. PLoS ONE, 2019, 14, e0222212.	2.5	21
303	Don't forget "Age" is a relevant variable in defining SuperAgers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 560-561.	2.4	14
304	Rates of age-associated amyloid $\beta$ associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	2.4	21
305	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 670-678.	2.4	19
306	Dietary Patterns and Cognitive Health in Older Adults: A Systematic Review. Journal of Alzheimer's Disease, 2019, 67, 583-619.	2.6	145
307	Klotho allele status is not associated with $\beta$ and APOE $\epsilon$ 4 related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	3.1	23
308	Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	1.9	60
309	Method comparison study of the Elecsys® $\beta$ -Amyloid (1 $\times$ 42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	1.9	30
310	A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data. Alzheimer's and Dementia, 2019, 15, 1059-1070.	0.8	151

#	ARTICLE	IF	CITATIONS
311	COMT val158met is not associated with A $\beta$ <sup>2</sup> -amyloid and APOE $\epsilon$ 4 related cognitive decline in cognitively normal older adults. <i>IBRO Reports</i> , 2019, 6, 147-152.	0.3	5
312	Preventing Alzheimer's: Our Most Urgent Health Care Priority. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 451-461.	1.9	18
314	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	1.9	18
315	Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. <i>Computational and Mathematical Methods in Medicine</i> , 2019, 2019, 1-8.	1.3	36
316	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019, 92, e1567-e1579.	1.1	73
317	The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1211-1228.	2.6	23
318	Multivariate Prediction of Hippocampal Atrophy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1453-1468.	2.6	2
319	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid $\beta$ load in preclinical Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 591-600.	1.3	18
320	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	10.3	59
321	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. <i>Scientific Reports</i> , 2019, 9, 17069.	3.3	15
322	Classification of Alzheimer's Disease using volumetric features of multiple MRI scans. , 2019, 2019, 2396-2401.		8
323	Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 515-523.	3.7	4
324	The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive impairment: a protocol for a randomized, controlled three-arm trial. <i>BMC Neurology</i> , 2019, 19, 326.	1.8	17
325	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ -Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , 2019, 8, 129-145.	3.2	8
326	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.8	310
327	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
328	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S187-S205.	2.6	18
329	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. <i>NeuroImage</i> , 2019, 186, 446-454.	4.2	16

#	ARTICLE	IF	CITATIONS
330	Regaining pre-fracture basic mobility status after hip fracture and association with post-discharge mortality and readmission—a nationwide register study in Denmark. <i>Age and Ageing</i> , 2019, 48, 278-284.	1.6	36
331	Machine learning studies on major brain diseases: 5-year trends of 2014–2018. <i>Japanese Journal of Radiology</i> , 2019, 37, 34-72.	2.4	100
332	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A $\beta$ -C-reactive protein™ for psychiatrists and neurologists?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 57-67.	2.3	40
333	Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 505-513.	3.4	35
334	Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 55-65.	1.3	10
335	Long-married couples recall their wedding day: the influence of collaboration and gender on autobiographical memory recall. <i>Memory</i> , 2020, 28, 18-33.	1.7	10
336	Identification of Pre-Clinical Alzheimer™s Disease in a Population of Elderly Cognitively Normal Participants. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 683-693.	2.6	0
337	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 183-193.	1.3	10
338	Deep learning to detect Alzheimer's disease from neuroimaging: A systematic literature review. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 187, 105242.	4.7	198
339	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- $\beta^2$ on Alzheimer™s Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	2.6	21
340	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. <i>Journal of Neurochemistry</i> , 2021, 159, 389-402.	3.9	20
341	The Association Between Anemia of Chronic Inflammation and Alzheimer™s Disease and Related Dementias. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 379-391.	2.2	12
342	Association of $\beta^2$ -Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. <i>Neurology</i> , 2021, 96, e662-e670.	1.1	34
343	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer™s disease. <i>Nature Communications</i> , 2020, 11, 5698.	12.8	76
344	Alzheimer's Disease Detection Through Whole-Brain 3D-CNN MRI. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 534592.	4.1	61
345	CHI study: protocol for an observational cohort study on ageing and mental health in community-dwelling older adults. <i>BMJ Open</i> , 2020, 10, e035003.	1.9	24
346	Attention-Guided Hybrid Network for Dementia Diagnosis With Structural MR Images. <i>IEEE Transactions on Cybernetics</i> , 2022, 52, 1992-2003.	9.5	43
347	Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimer™s Disease in the AIBL Study of Ageing. <i>Life</i> , 2020, 10, 141.	2.4	2

#	ARTICLE	IF	CITATIONS
348	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. <i>NeuroImage: Clinical</i> , 2020, 28, 102479.	2.7	19
349	Does size matter? The relationship between predictive power of single-subject morphometric networks to spatial scale and edge weight. <i>Brain Structure and Function</i> , 2020, 225, 2475-2493.	2.3	10
350	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 733-744.	2.6	7
351	Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture. <i>Nature Communications</i> , 2020, 11, 4799.	12.8	110
352	Association of deficits in short-term learning and A $\beta$ and hippocampal volume in cognitively normal adults. <i>Neurology</i> , 2020, 95, e2577-e2585.	1.1	31
353	Plasma Amyloid- $\beta$ Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1057-1065.	2.6	27
354	Unsupervised assessment of cognition in the Healthy Brain Project: Implications for web-based registries of individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12043.	3.7	34
355	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- $\beta$ plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 140, 463-476.	7.7	34
356	Cellular correlates of cortical thinning throughout the lifespan. <i>Scientific Reports</i> , 2020, 10, 21803.	3.3	80
357	Validation and Reliability of the Alzheimer's Disease-Commonwealth Scientific and Industrial Research Organisation Food Frequency Questionnaire. <i>Nutrients</i> , 2020, 12, 3605.	4.1	3
358	Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player. <i>Frontiers in Neurology</i> , 2020, 11, 598980.	2.4	16
359	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2020, 14, 556137.	2.8	20
360	A recommended minimum data set framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer's Study (ARIAS). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12119.	2.4	3
361	Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation. <i>Medical Image Analysis</i> , 2020, 63, 101694.	11.6	351
362	Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 59.	6.2	35
363	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	2.6	13
364	Brain amyloid in virally suppressed HIV-associated neurocognitive disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	22
365	Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1766822.	12.2	59

#	ARTICLE	IF	CITATIONS
366	Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 571-577.	2.6	6
367	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 303-315.	2.6	23
368	Plasma transferrin and hemopexin are associated with altered A $\beta$ uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 72.	6.2	19
369	Serum vitamin B12 and related 5-methyltetrahydrofolate-homocysteine methyltransferase reductase and cubilin genotypes predict neural outcomes across the Alzheimer's disease spectrum. <i>British Journal of Nutrition</i> , 2020, 124, 135-145.	2.3	2
370	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	2.4	35
371	Estimating brain age based on a uniform healthy population with deep learning and structural magnetic resonance imaging. <i>Neurobiology of Aging</i> , 2020, 91, 15-25.	3.1	48
372	Spatially-Constrained Fisher Representation for Brain Disease Identification With Incomplete Multi-Modal Neuroimages. <i>IEEE Transactions on Medical Imaging</i> , 2020, 39, 2965-2975.	8.9	52
373	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- $\beta$ Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301.	2.6	3
374	Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 1879-1892.	3.7	9
375	Association Between Cognitive Function and Clustered Cardiovascular Risk of Metabolic Syndrome in Older Adults at Risk of Cognitive Decline. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 300-304.	3.3	17
376	Challenges of Integrative Disease Modeling in Alzheimer's Disease. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 158.	3.5	13
377	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 115.	3.4	7
378	Total A $\beta$ <sub>42</sub> / A $\beta$ <sub>40</sub> ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. <i>Neurology</i> , 2020, 94, e1580-e1591.	1.1	102
379	Multisession transcranial direct current stimulation facilitates verbal learning and memory consolidation in young and older adults. <i>Brain and Language</i> , 2020, 205, 104788.	1.6	24
380	From a deep learning model back to the brain—Identifying regional predictors and their relation to aging. <i>Human Brain Mapping</i> , 2020, 41, 3235-3252.	3.6	62
381	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. <i>International Journal of Neuroscience</i> , 2021, 131, 800-809.	1.6	14
382	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 36.	6.2	39
383	Increased glutaminy cyclase activity in brains of Alzheimer's disease individuals. <i>Journal of Neurochemistry</i> , 2021, 156, 979-987.	3.9	11

#	ARTICLE	IF	CITATIONS
384	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.8	3
385	Detect and correct bias in multi-site neuroimaging datasets. Medical Image Analysis, 2021, 67, 101879.	11.6	62
386	Deep Bayesian Hashing With Center Prior for Multi-Modal Neuroimage Retrieval. IEEE Transactions on Medical Imaging, 2021, 40, 503-513.	8.9	11
387	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- $\beta$ -negative cognitively normal individuals. Neurobiology of Aging, 2021, 97, 41-48.	3.1	23
388	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology, 2021, 96, e619-e631.	1.1	45
389	A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). NeuroImage: Clinical, 2021, 29, 102527.	2.7	19
391	Learning Transferable 3D-CNN for MRI-Based Brain Disorder Classification from Scratch: An Empirical Study. Lecture Notes in Computer Science, 2021, , 10-19.	1.3	1
392	Polygenic score modifies risk for Alzheimer's disease in <i>APOE</i> $\epsilon$ 4 homozygotes at phenotypic extremes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12226.	2.4	7
393	Learning deficit in cognitively normal <i>APOE</i> $\epsilon$ 4 carriers with LOW $\beta$ -amyloid. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12136.	2.4	7
394	Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-10.	2.7	0
395	Disease-Image-Specific Learning for Diagnosis-Oriented Neuroimage Synthesis With Incomplete Multi-Modality Data. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2022, 44, 6839-6853.	13.9	33
396	Association of naturally occurring antibodies to $\beta$ -amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. Science Advances, 2021, 7, .	10.3	26
397	Construction of MRI-Based Alzheimer's Disease Score Based on Efficient 3D Convolutional Neural Network: Comprehensive Validation on 7,902 Images from a Multi-Center Dataset. Journal of Alzheimer's Disease, 2021, 79, 47-58.	2.6	17
398	Deep Grading Based on Collective Artificial Intelligence for AD Diagnosis and Prognosis. Lecture Notes in Computer Science, 2021, , 24-33.	1.3	2
399	<i>BDNF</i> VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. Genes, Brain and Behavior, 2021, 20, e12724.	2.2	14
400	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. NeuroImage, 2021, 226, 117593.	4.2	15
401	Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. Journal of Neuroimaging, 2021, 31, 569-578.	2.0	68
402	Comparing different approaches for operationalizing subjective cognitive decline: impact on syndromic and biomarker profiles. Scientific Reports, 2021, 11, 4356.	3.3	17

#	ARTICLE	IF	CITATIONS
403	Visual Memory Deficits in Middle-Aged APOE ε4 Homozygotes Detected Using Unsupervised Cognitive Assessments. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1563-1573.	2.6	4
405	SPON1 Is Associated with Amyloid-β <sup>2</sup> and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 111-120.	2.2	5
406	Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 721.	12.8	67
407	Toward a Universal Readout for <sup>18</sup> F-Labeled Amyloid Tracers: The CAPTAINs Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 999-1005.	5.0	9
408	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	8.8	49
409	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	7.3	27
410	Quantity and quality: Normative open-access neuroimaging databases. <i>PLoS ONE</i> , 2021, 16, e0248341.	2.5	3
411	A Modified Convolutional Neural Networks For MRI-based Images For Detection and Stage Classification Of Alzheimer Disease. , 2021, , .		5
412	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021, 96, 944-954.	1.1	14
413	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1479-1489.	2.6	4
414	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	6.4	16
415	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 79.	6.2	0
416	U-net-based analysis of MRI for Alzheimer's disease diagnosis. <i>Neural Computing and Applications</i> , 2021, 33, 13587-13599.	5.6	18
417	Scan Once, Analyse Many: Using Large Open-Access Neuroimaging Datasets to Understand the Brain. <i>Neuroinformatics</i> , 2022, 20, 109-137.	2.8	20
418	KL-VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE ε4 carriers. <i>Neurobiology of Aging</i> , 2021, 101, 123-129.	3.1	10
419	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. <i>Hormones and Behavior</i> , 2021, 131, 104966.	2.1	2
420	A predictive framework based on brain volume trajectories enabling early detection of Alzheimer's disease. <i>Computerized Medical Imaging and Graphics</i> , 2021, 90, 101910.	5.8	20
421	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	2.2	59



#	ARTICLE	IF	CITATIONS
422	Comparison of Automated Volume Extraction with FreeSurfer and FastSurfer for Early Alzheimer's Disease Detection with Machine Learning. , 2021, , .		1
423	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 1039-1052.	2.6	2
424	Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling. Alzheimer's and Dementia, 2022, 18, 251-261.	0.8	18
425	Multi-site MRI harmonization via attention-guided deep domain adaptation for brain disorder identification. Medical Image Analysis, 2021, 71, 102076.	11.6	65
427	Computer-aided diagnosis of Alzheimer's disease by MRI analysis and evolutionary computing. Research on Biomedical Engineering, 2021, 37, 455-483.	2.2	2
430	Synthetic microbleeds generation for classifier training without ground truth. Computer Methods and Programs in Biomedicine, 2021, 207, 106127.	4.7	6
431	Comparison of traveling subject and ComBat harmonization methods for assessing structural brain characteristics. Human Brain Mapping, 2021, 42, 5278-5287.	3.6	47
432	Using normative modelling to detect disease progression in mild cognitive impairment and Alzheimer's disease in a cross-sectional multi-cohort study. Scientific Reports, 2021, 11, 15746.	3.3	37
433	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. Journal of Alzheimer's Disease, 2021, 83, 1233-1249.	2.6	7
434	The Support Person's Preferences and Perspectives of Physical Activity Programs for Older Adults With Cognitive Impairment. Frontiers in Public Health, 2021, 9, 704561.	2.7	3
435	Enhancing Alzheimer's Disease Diagnosis via Hierarchical 3D-FCN with Multi-Modal Features. , 2021, , .		0
436	Data analysis with Shapley values for automatic subject selection in Alzheimer's disease data sets using interpretable machine learning. Alzheimer's Research and Therapy, 2021, 13, 155.	6.2	18
438	Structural volume and cortical thickness differences between males and females in cognitively normal, cognitively impaired and Alzheimer's dementia population. Neurobiology of Aging, 2021, 106, 1-11.	3.1	7
439	Large, open datasets for human connectomics research: Considerations for reproducible and responsible data use. NeuroImage, 2021, 244, 118579.	4.2	35
440	MRI-based Alzheimer's disease prediction via distilling the knowledge in multi-modal data. NeuroImage, 2021, 244, 118586.	4.2	17
441	Neuroepidemiology: New Methods, Results, and Challenges in the Definition of the Early Phases of Alzheimer's Disease: Insights From Subjective Memory Complaints and Subjective Cognitive Decline. , 2022, , 26-42.		0
442	Feature selection using efficient fusion of Fisher Score and greedy searching for Alzheimer's disease classification. Journal of King Saud University - Computer and Information Sciences, 2022, 34, 4993-5006.	3.9	12
443	Transfer learning-trained convolutional neural networks identify novel MRI biomarkers of Alzheimer's disease progression. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12140.	2.4	17

#	ARTICLE	IF	CITATIONS
444	Relationship between amyloid and tau levels and its impact on tau spreading. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2225-2232.	6.4	30
445	Evaluating the Alzheimer's disease data landscape. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12102.	3.7	24
446	Quantifying Confounding Bias in Neuroimaging Datasets with Causal Inference. <i>Lecture Notes in Computer Science</i> , 2019, , 484-492.	1.3	8
447	Generative Aging of Brain MR-Images and Prediction of Alzheimer Progression. <i>Lecture Notes in Computer Science</i> , 2019, , 247-260.	1.3	8
448	Attention-Guided Deep Domain Adaptation for Brain Dementia Identification with Multi-site Neuroimaging Data. <i>Lecture Notes in Computer Science</i> , 2020, , 31-40.	1.3	5
449	Accurate Whole-Brain Segmentation for Alzheimer's Disease Combining an Adaptive Statistical Atlas and Multi-atlas. <i>Lecture Notes in Computer Science</i> , 2014, 8331, 65-73.	1.3	3
451	HIST: HyperIntensity Segmentation Tool. <i>Lecture Notes in Computer Science</i> , 2016, , 92-99.	1.3	5
452	What did you do yesterday? A meta-analysis of sex differences in episodic memory.. <i>Psychological Bulletin</i> , 2019, 145, 785-821.	6.1	117
453	Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.. <i>Neuropsychology</i> , 2019, 33, 964-974.	1.3	17
454	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study.. <i>Psychological Assessment</i> , 2018, 30, 1308-1316.	1.5	5
462	Classification of brain MRI with big data and deep 3D convolutional neural networks. , 2018, , .		37
463	Association of Plasma A $\beta$ Peptides with Blood Pressure in the Elderly. <i>PLoS ONE</i> , 2011, 6, e18536.	2.5	19
464	Design and Validation of a Novel Method to Measure Cross-Sectional Area of Neck Muscles Included during Routine MR Brain Volume Imaging. <i>PLoS ONE</i> , 2012, 7, e34444.	2.5	18
465	Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials. <i>PLoS ONE</i> , 2013, 8, e58816.	2.5	38
466	A Systematic Review of Medication Exposure Assessment in Prospective Cohort Studies of Community Dwelling Older Australians. <i>PLoS ONE</i> , 2015, 10, e0124247.	2.5	4
467	Assessing Error Awareness as a Mediator of the Relationship between Subjective Concerns and Cognitive Performance in Older Adults. <i>PLoS ONE</i> , 2016, 11, e0166315.	2.5	4
468	Decreased Platelet APP Isoform Ratios in Autosomal Dominant Alzheimer's Disease: Baseline Data from a DIAN Cohort Subset. <i>Current Alzheimer Research</i> , 2015, 12, 157-164.	1.4	10
469	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 787-799.	1.4	23

#	ARTICLE	IF	CITATIONS
470	Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	2.6	4
471	Gene-environment interactions in considering physical activity for the prevention of dementia. AIMS Molecular Science, 2015, 2, 359-381.	0.5	2
472	En Attendant Centiloid. Advances in Research, 2014, 2, 723-729.	0.3	32
473	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. NeuroImage: Clinical, 2021, 32, 102864.	2.7	13
474	Domain Adaptation for Medical Image Analysis: A Survey. IEEE Transactions on Biomedical Engineering, 2022, 69, 1173-1185.	4.2	218
475	Demencia prevenci3: A korai diagn3zist3l a szem3lyre szabott intervenci3ig. Scientia Et Securitas, 2021, 2, 207-219.	0.2	0
476	Bayesian inference and dynamic prediction of multivariate joint model with functional data: An application to Alzheimer's disease. Statistics in Medicine, 2021, 40, 6855.	1.6	1
477	Focal Ab-amyloid deposition precedes cerebral microbleeds and Superficial siderosis: a case report. , 2017, 1, 039-044.		1
482	Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. Journal of Psychiatry and Brain Science, 2019, 4, .	0.5	3
483	Deep Disentangled Hashing with Momentum Triplets for Neuroimage Search. Lecture Notes in Computer Science, 2020, 12261, 191-201.	1.3	3
486	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A $\beta$ load and cerebrospinal fluid A $\beta$ in a pilot study of Alzheimer's disease. Neuroscience Letters, 2020, 731, 135078.	2.1	6
488	3D hemisphere-based convolutional neural network for whole-brain MRI segmentation. Computerized Medical Imaging and Graphics, 2022, 95, 102000.	5.8	12
489	A multi-scanner neuroimaging data harmonization using RAVEL and ComBat. NeuroImage, 2021, 245, 118703.	4.2	31
490	Assessing clinical progression from subjective cognitive decline to mild cognitive impairment with incomplete multi-modal neuroimages. Medical Image Analysis, 2022, 75, 102266.	11.6	19
491	A Bayesian Hierarchical Approach to Jointly Model Cortical Thickness and Covariance Networks. Lecture Notes in Mathematics, 2020, , 155-213.	0.2	0
492	A $\beta$ Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
493	Identifying Key Predictors of Cognitive Dysfunction in Older People Using Supervised Machine Learning Techniques: Observational Study. JMIR Medical Informatics, 2020, 8, e20995.	2.6	6
495	DenseCNN: A Densely Connected CNN Model for Alzheimer's Disease Classification Based on Hippocampus MRI Data. AMIA ... Annual Symposium proceedings, 2020, 2020, 1277-1286.	0.2	1

#	ARTICLE	IF	CITATIONS
496	Longitudinal Cognitive Decline in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 1-6.	2.7	3
497	Machine learning techniques for diagnosis of Alzheimer disease, mild cognitive disorder, and other types of dementia. <i>Biomedical Signal Processing and Control</i> , 2022, 72, 103293.	5.7	69
498	Individual variations in "brain age" relate to early-life factors more than to longitudinal brain change. <i>ELife</i> , 2021, 10, .	6.0	71
499	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. <i>Brain Imaging and Behavior</i> , 2021, 15, 2833-2842.	2.1	1
500	5 Years of Exercise Intervention Did Not Benefit Cognition Compared to the Physical Activity Guidelines in Older Adults, but Higher Cardiorespiratory Fitness Did. A Generation 100 Substudy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 742587.	3.4	11
501	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	2.6	1
503	A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty. <i>Frontiers in Digital Health</i> , 2021, 3, 780303.	2.8	2
504	Machine learning, artificial intelligence and the prediction of dementia. <i>Current Opinion in Psychiatry</i> , 2022, 35, 123-129.	6.3	21
505	Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 1-7.	2.7	2
506	Measurement of Subjective Cognitive Decline (SCD) Using Korean-Everyday Cognition (K-ECog) as a Screening Tool: a Feasibility Study. <i>Dementia and Neurocognitive Disorders</i> , 2021, 20, 80.	1.4	3
508	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease. <i>Proteome Science</i> , 2022, 20, 2.	1.7	6
509	Utility of Diffusion Modeling of Cogstate Brief Battery Test Performance in Detecting Mild Cognitive Impairment. <i>Assessment</i> , 2023, 30, 847-855.	3.1	1
510	Stroke population-specific neuroanatomical CT-MRI brain atlas. <i>Neuroradiology</i> , 2022, , 1.	2.2	1
511	<i>APOE</i> $\epsilon$ 2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. <i>Alzheimer's and Dementia</i> , 2022, 18, 2151-2166.	0.8	16
512	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233.	0.8	24
513	Designing a clinical decision support system for Alzheimer's diagnosis on OASIS-3 data set. <i>Biomedical Signal Processing and Control</i> , 2022, 74, 103527.	5.7	10
514	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12307.	2.4	14
517	A Targeted Association Study of Blood-Brain Barrier Gene SNPs and Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-13.	2.6	0

#	ARTICLE	IF	CITATIONS
519	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 771214.	3.4	8
520	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 51-81.	2.6	14
522	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.8	15
523	A Single Model Deep Learning Approach for Alzheimer's Disease Diagnosis. <i>Neuroscience</i> , 2022, 491, 200-214.	2.3	17
524	Mesial temporal tau in amyloid- $\beta$ -negative cognitively normal older persons. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 51.	6.2	12
525	PET image harmonization using smoothing-cycleGAN. , 2022, , .		1
526	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. <i>Science Advances</i> , 2022, 8, eabm5667.	10.3	6
527	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	6.4	34
528	Long-term stability and age-dependence of six regulatory serum proteins. <i>Biomarkers in Medicine</i> , 2022, 16, 511-521.	1.4	3
529	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A $\beta$ 242 moderates the association between insulin resistance and increased CSF tau levels. <i>Neurobiology of Aging</i> , 2022, 114, 38-48.	3.1	5
530	Federated Learning via Conditional Mutual Learning for Alzheimer's Disease Classification on T1w MRI. , 2021, 2021, 2427-2432.		2
531	Alzheimer's disease classification accuracy is Improved by MRI harmonization based on attention-guided generative adversarial networks. , 2021, 12088, .		5
532	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. <i>Scientific Reports</i> , 2021, 11, 23788.	3.3	16
533	Validation of Plasma Amyloid- $\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.1	89
534	Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 55.	6.2	2
535	Enhanced Fuzzy Elephant Herding Optimization-Based OTSU Segmentation and Deep Learning for Alzheimer's Disease Diagnosis. <i>Mathematics</i> , 2022, 10, 1259.	2.2	8
536	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. <i>GeroScience</i> , 2022, 44, 1807-1823.	4.6	19
539	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in A $\beta$ <sup>-</sup> and A $\beta$ <sup>+</sup> Older Adults. <i>Neurology</i> , 2022, 98, e1704-e1715.	1.1	4

#	ARTICLE	IF	CITATIONS
540	Deviation From Model of Normal Aging in Alzheimer's Disease: Application of Deep Learning to Structural MRI Data and Cognitive Tests. <i>IEEE Access</i> , 2022, 10, 53234-53249.	4.2	6
541	A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	2.7	2
542	Structural progression of Alzheimer's disease over decades: the MRI staging scheme. <i>Brain Communications</i> , 2022, 4, fca109.	3.3	35
543	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. <i>Biomedicine</i> , 2022, 10, 1045.	3.2	1
544	Construction of a confounder-free clinical MRI dataset in the Mass General Brigham system for classification of Alzheimer's disease. <i>Artificial Intelligence in Medicine</i> , 2022, 129, 102309.	6.5	8
545	ADaTViewer: exploring semantically harmonized Alzheimer's disease cohort datasets. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	6
546	Non-standard pipeline without MRI has replicability in computation of Centiloid scale values for PiB and 18F-labeled amyloid PET tracers. <i>NeuroImage Reports</i> , 2022, 2, 100101.	1.0	1
547	Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease. <i>BMC Genomics</i> , 2022, 23, .	2.8	1
548	Hippocampal representations for deep learning on Alzheimer's disease. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
549	Data Augmentation in High Dimensional Low Sample Size Setting Using a Geometry-Based Variational Autoencoder. <i>IEEE Transactions on Pattern Analysis and Machine Intelligence</i> , 2022, , 1-18.	13.9	14
550	Multimodal deep learning for Alzheimer's disease dementia assessment. <i>Nature Communications</i> , 2022, 13, .	12.8	65
551	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. <i>Nature Communications</i> , 2022, 13, .	12.8	30
552	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE- $\epsilon$ 4 in female patients with Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 616-634.	11.6	11
553	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	2.6	7
554	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7867.	4.1	5
556	Plasma A $\beta$ 42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 1117-1134.	0.8	44
557	Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies.. <i>Neuropsychology</i> , 2023, 37, 436-449.	1.3	3
558	Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. <i>Journal of Neurochemistry</i> , 2022, 163, 53-67.	3.9	6

#	ARTICLE	IF	CITATIONS
559	Goal-specific brain MRI harmonization. <i>NeuroImage</i> , 2022, 263, 119570.	4.2	10
560	Quantifiable brain atrophy synthesis for benchmarking of cortical thickness estimation methods. <i>Medical Image Analysis</i> , 2022, 82, 102576.	11.6	9
561	Generating novel pituitary datasets from open-source imaging data and deep volumetric segmentation. <i>Pituitary</i> , 0, , .	2.9	0
562	Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, .	12.8	24
563	Cognitive domain harmonization and cocalibration in studies of older adults.. <i>Neuropsychology</i> , 2023, 37, 409-423.	1.3	20
564	Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand. <i>Journal of the Royal Society of New Zealand</i> , 0, , 1-22.	1.9	2
565	DAFT: A universal module to interweave tabular data and 3D images in CNNs. <i>NeuroImage</i> , 2022, 260, 119505.	4.2	8
566	$\beta$ -amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3. <i>NeuroImage</i> , 2022, 262, 119527.	4.2	10
567	Accurate and Explainable Image-Based Prediction Using a Lightweight Generative Model. <i>Lecture Notes in Computer Science</i> , 2022, , 448-458.	1.3	0
568	Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	6
569	Interpretable Differential Diagnosis for Alzheimer's Disease and Frontotemporal Dementia. <i>Lecture Notes in Computer Science</i> , 2022, , 55-65.	1.3	5
571	Machine Learning Workflow to Explain Black-Box Models for Early Alzheimer's Disease Classification Evaluated for Multiple Datasets. <i>SN Computer Science</i> , 2022, 3, .	3.6	5
572	Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 31-37.	1.9	3
573	BrainGB: A Benchmark for Brain Network Analysis With Graph Neural Networks. <i>IEEE Transactions on Medical Imaging</i> , 2023, 42, 493-506.	8.9	20
574	Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease. <i>The Lancet Healthy Longevity</i> , 2022, 3, e797-e803.	4.6	6
575	Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study. <i>PLoS ONE</i> , 2022, 17, e0277322.	2.5	6
577	Learning to restore multiple image degradations simultaneously. <i>Pattern Recognition</i> , 2023, 136, 109250.	8.1	0
578	Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	3

#	ARTICLE	IF	CITATIONS
580	â€œI remember where the galaxies are and you remember where the stocks areâ€™: Older couplesâ€™ descriptions of transactive memory systems in everyday life. <i>Journal of Social and Personal Relationships</i> , 0, , 026540752211447.	2.3	0
582	Towards better interpretable and generalizable AD detection using collective artificial intelligence. <i>Computerized Medical Imaging and Graphics</i> , 2023, 104, 102171.	5.8	1
583	Neuropsychology in Australia: A multidimensional perspective. , 2019, 1, 72-81.		0
584	The relationship between objective physical activity and change in cognitive function. <i>Alzheimer's and Dementia</i> , 2023, 19, 2984-2993.	0.8	3
585	Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	4
586	Estimating uncertainty in readâ€œut patterns: Application to controlsâ€œbased denoising and voxelâ€œbased morphometry patterns in neurodegenerative and neuropsychiatric diseases. <i>Human Brain Mapping</i> , 2023, 44, 2802-2814.	3.6	3
587	Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. <i>Nature Medicine</i> , 2023, 29, 1221-1231.	30.7	66
588	Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study. <i>EBioMedicine</i> , 2023, 88, 104450.	6.1	10
589	Ensemble Classifiers for a 4-Way Classification of Alzheimerâ€™s Disease. <i>Communications in Computer and Information Science</i> , 2022, , 219-230.	0.5	5
590	Discovery of a Missense Mutation (Q222K) of the APOE Gene from the Australian Imaging, Biomarker and Lifestyle Study. <i>Journal of Alzheimer's Disease Reports</i> , 2023, 7, 165-172.	2.2	0
591	Conventional machine learning and deep learning in Alzheimer's disease diagnosis using neuroimaging: A review. <i>Frontiers in Computational Neuroscience</i> , 0, 17, .	2.1	22
593	Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 615-628.	2.6	11
594	Forecasting individual progression trajectories in Alzheimerâ€™s disease. <i>Nature Communications</i> , 2023, 14, .	12.8	7
595	Detecting mild cognitive impairment and dementia in older adults using naturalistic driving data and interaction-based classification from influence score. <i>Artificial Intelligence in Medicine</i> , 2023, 138, 102510.	6.5	1
596	Deep-Learning-Based Diagnosis and Prognosis of Alzheimerâ€™s Disease: A Comprehensive Review. <i>IEEE Transactions on Cognitive and Developmental Systems</i> , 2023, 15, 1123-1138.	3.8	12
597	Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 765-778.	3.7	4
598	Alzheimerâ€™s disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	4
599	Three-round learning strategy based on 3D deep convolutional GANs for Alzheimerâ€™s disease staging. <i>Scientific Reports</i> , 2023, 13, .	3.3	1



#	ARTICLE	IF	CITATIONS
600	Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
602	Improving Alzheimer's Disease Diagnosis With Multi-Modal PET Embedding Features by a 3D Multi-Task MLP-Mixer Neural Network. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2023, 27, 4040-4051.	6.3	5
603	Machine Learning Models for Diagnosing Alzheimer's Disorders. <i>Cognitive Technologies</i> , 2023, , 183-194.	0.8	0
604	Tau in dementia with Lewy bodies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2024, 58, 175-182.	2.3	2
605	Habitual dietary nitrate intake and cognition in the Australian Imaging, Biomarkers and Lifestyle Study of ageing: A prospective cohort study. <i>Clinical Nutrition</i> , 2023, 42, 1251-1259.	5.0	2
606	A Survey of Deep Learning for Alzheimer's Disease. <i>Machine Learning and Knowledge Extraction</i> , 2023, 5, 611-668.	5.0	6
607	CSF A $\beta$ 242 and tau biomarkers in cognitively unimpaired A $\beta$ 2- $\beta$ middle-aged and older APOE $\epsilon$ 4 carriers. <i>Neurobiology of Aging</i> , 2023, 129, 209-218.	3.1	4
609	Hippocampal grading provides higher classification accuracy for those in the AD trajectory than hippocampal volume. <i>Human Brain Mapping</i> , 2023, 44, 4623-4633.	3.6	0
610	Sixteen-Year Longitudinal Evaluation of Blood-Based DNA Methylation Biomarkers for Early Prediction of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 94, 1443-1464.	2.6	0
611	Assessing subjective cognitive decline in older adults attending primary health care centers: what question should be asked?. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2023, 45, 313-320.	1.3	0
612	Cascaded Multi-Modal Mixing Transformers for Alzheimer's Disease Classification with Incomplete Data. <i>NeuroImage</i> , 2023, 277, 120267.	4.2	6
613	Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN). <i>Nature Neuroscience</i> , 2023, 26, 1449-1460.	14.8	4
615	Challenges of implementing computer-aided diagnostic models for neuroimages in a clinical setting. <i>Npj Digital Medicine</i> , 2023, 6, .	10.9	7
616	A universal neocortical mask for Centiloid quantification. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.4	0
617	Main Existing Datasets for Open Brain Research on Humans. <i>NeuroMethods</i> , 2023, , 753-804.	0.3	0
618	A robust harmonization approach for cognitive data from multiple aging and dementia cohorts. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.4	1
619	Exploring the potential impact of multi-factor precision interventions in Alzheimer's disease with system dynamics. <i>Journal of Biomedical Informatics</i> , 2023, 145, 104462.	4.3	1
620	The minimum data set of electronic personal health records for Alzheimer's disease using design science methodology. <i>Health Policy and Technology</i> , 2023, 12, 100785.	2.5	0

#	ARTICLE	IF	CITATIONS
621	Resizer Swin Transformer-Based Classification Using sMRI for Alzheimer's Disease. Applied Sciences (Switzerland), 2023, 13, 9310.	2.5	1
622	Evaluation of novel data-driven metrics of amyloid $\beta^2$ deposition for longitudinal PET studies. NeuroImage, 2023, 280, 120313.	4.2	0
623	Self-Supervised Contrastive Learning to Predict the Progression of Alzheimer's Disease with 3D Amyloid-PET. Bioengineering, 2023, 10, 1141.	3.5	0
624	Risk, protective, and biomarkers of dementia in Indigenous peoples: A systematic review. Alzheimer's and Dementia, 2024, 20, 563-592.	0.8	0
625	Explainable deep learning in plant phenotyping. Frontiers in Artificial Intelligence, 0, 6, .	3.4	1
626	DSMRI: Domain Shift Analyzer for Multi-Center MRI Datasets. Diagnostics, 2023, 13, 2947.	2.6	1
627	Cognitive Trajectories in Preclinical and Prodromal Alzheimer's Disease Related to Amyloid Status and Brain Atrophy: A Bayesian Approach. Journal of Alzheimer's Disease Reports, 2023, 7, 1055-1076.	2.2	0
628	Early prediction of progression to Alzheimer's disease using multi-modality neuroimages by a novel ordinal learning model ADPacer. IJSE Transactions on Healthcare Systems Engineering, 0, , 1-11.	1.7	0
629	Longitudinal trajectories of basal forebrain volume in normal aging and Alzheimer's disease. Neurobiology of Aging, 2023, 132, 120-130.	3.1	2
630	Cross-modality Neuroimage Synthesis: A Survey. ACM Computing Surveys, 2024, 56, 1-28.	23.0	1
632	Transformers and their application to medical image processing: A review. Journal of Radiation Research and Applied Sciences, 2023, , 100680.	1.2	0
633	Domain Adaptation of fMRI Scanners as an Alternative to fMRI Harmonization. Lecture Notes in Computer Science, 2024, , 1-11.	1.3	2
635	Sex-dependent cholinergic effects on amyloid pathology: A translational study. Alzheimer's and Dementia, 2024, 20, 995-1012.	0.8	2
636	Neuronanomedicine for Alzheimer's and Parkinson's disease: Current progress and a guide to improve clinical translation. Brain, Behavior, and Immunity, 2024, 115, 631-651.	4.1	1
637	Joint learning framework of cross-modal synthesis and diagnosis for Alzheimer's disease by mining underlying shared modality information. Medical Image Analysis, 2024, 91, 103032.	11.6	0
639	Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 96, 1781-1799.	2.6	0
640	Multimodal Neuroimaging for Early Alzheimer's detection: A Deep Learning Approach. , 2023, , .		0
641	Subjective cognitive decline and cerebral-cognitive reserve in late age. Translational Medicine of Aging, 2023, 7, 137-147.	1.3	0

#	ARTICLE	IF	CITATIONS
642	Association Between $\beta$ -Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia. <i>Neurology</i> , 2024, 102, .	1.1	0
644	Machine Learning-Derived MRI-Based Neurodegeneration Biomarker for Alzheimer's Disease: A Multi-Database Validation Study. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 883-893.	2.6	0
646	CNN-based Alzheimer's disease classification using fusion of multiple 3D angular orientations. <i>Signal, Image and Video Processing</i> , 2024, 18, 2743-2751.	2.7	0
647	Equilibrium of Dietary Patterns Between Alzheimer's Disease Patients and Healthy People: A Comprehensive Analysis Using Multiple Factor Analysis and Classification Modeling. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 777-790.	2.6	0
648	Learning multi-site harmonization of magnetic resonance images without traveling human phantoms. , 2024, 3, .		0
649	Gene-SGAN: discovering disease subtypes with imaging and genetic signatures via multi-view weakly-supervised deep clustering. <i>Nature Communications</i> , 2024, 15, .	12.8	2
650	Brain structure ages: A new biomarker for multi-disease classification. <i>Human Brain Mapping</i> , 2024, 45, .	3.6	0
653	Exploring sexual dimorphism in basal forebrain volume changes during aging and neurodegenerative diseases. <i>iScience</i> , 2024, 27, 109041.	4.1	0
654	Systematic comparison of 3D Deep learning and classical machine learning explanations for Alzheimer's Disease detection. <i>Computers in Biology and Medicine</i> , 2024, 170, 108029.	7.0	0
656	An Optimal Weighted Ensemble of 3D CNNs for Early Diagnosis of Alzheimer's Disease. <i>SN Computer Science</i> , 2024, 5, .	3.6	0
657	Early detection of dementia using artificial intelligence and multimodal features with a focus on neuroimaging: A systematic literature review. <i>Health and Technology</i> , 2024, 14, 201-237.	3.6	0
659	Exploring the association between cancer and cognitive impairment in the Australian Imaging Biomarkers and Lifestyle (AIBL) study. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
660	The power of many brains: Catalyzing neuropsychiatric discovery through open neuroimaging data and large-scale collaboration. <i>Science Bulletin</i> , 2024, , .	9.0	0